Healius Limited




Healthcare Facilities & Services

Market Closed - Australian S.E. 02:10:46 2024-04-19 am EDT 5-day change 1st Jan Change
1.205 AUD -0.41% Intraday chart for Healius Limited -0.82% -26.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight MT
Australia shares inch lower as miners weigh; GDP data in focus RE
Jarden Research Adjusts Healius’ Price Target to AU$1.26 From AU$1.29, Keeps at Underweight MT
Australian Shares Inch Up as Market Awaits Economic Data, US Fed Statements MT
Healius Shares Sink 6%; Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss MT
Healius Limited Provides Earnings Guidance for Second Half of 2024 and Fiscal Year 2024 CI
Transcript : Healius Limited, H1 2024 Earnings Call, Feb 27, 2024
Healius Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss MT
Healius Reports Wider H1 FY24 Loss as Revenue Slips 2% MT
Healius Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Healius Subsidiary Enters Commercial Deal with Geneva-based SGS MT
Australian shares on three-day winning streak; banks, miners lead RE
Australia shares starts 2024 higher on rate-cut hopes RE
Australian Clinical Labs Gets Regulator Approval to Withdraw Healius Takeover Offer MT
Australian Clinical Labs Limited cancelled the acquisition of Healius Limited from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others. CI
Australian shares end higher on miners, Fed rate pivot RE
US Fed's Dovish Stance Lifts Australian Shares MT
Australian Clinical Labs Intends to Withdraw Proposed Healius Takeover MT
Competition Regulator Denies Australian Clinical Labs’ Proposed Takeover of Healius MT
Australia shares hit over 4-mth high on boost from commodities, banks stocks RE
Australian Clinical Labs to withdraw $1 billion offer for Healius; stocks fall RE
Healius Limited Appoints Ravi Jeyaraj as Director CI
Transcript : Healius Limited - Shareholder/Analyst Call
Healius Limited Announces Chair Changes CI
Transcript : Healius Limited, Q1 2024 Sales/ Trading Statement Call, Nov 23, 2023
Chart Healius Limited
More charts
Healius Limited is an Australia-based healthcare company. The Company operates through two segments: Pathology and Imaging. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment is a provider of imaging and scanning services at standalone imaging sites, hospitals, and medical centers. The Company has a network of pathology laboratories, collection centers, and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. The Company’s brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. The Company provides healthcare services that are accessible and efficient while supporting the coordination and continuity of quality patient care.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
1.21 AUD
Average target price
1.364 AUD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. HLS Stock
  4. News Healius Limited
  5. Healius Subsidiary Enters Commercial Deal with Geneva-based SGS